Opens in a new tab or window Glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), were originally approved for type 2 diabetes ...
Our editors also may be in touch with follow-up questions. Due to a Wegovy shortage coupled with Ozempic’s weight loss effects going viral on social media, people without type 2 diabetes have ...